Navigation Links
Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Date:2/11/2008

NEW YORK, Feb. 11 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals announced today that the last subject randomized into the SUN-Micro Phase 3 clinical trial has completed their scheduled 8 month visit. This milestone officially marks the completion of this pivotal clinical trial of its investigational drug Sulonex(TM) (sulodexide oral gelcap) in the treatment of subjects with type 2 diabetes and persistent microalbuminuria despite treatment with the maximum approved or tolerated dose of either an Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB). This randomized, double-blind, placebo-controlled study enrolled 1,056 subjects at over 150 sites worldwide.

The Company anticipates being able to report top-line results from this study before the end of March 2008, and expects that the Collaborative Study Group will make a comprehensive scientific presentation of the data at a medical conference in the 2nd or 3rd quarter. The Company is targeting an NDA filing before year end.

"The completion of the Sulonex Phase 3 clinical program is an important and significant milestone for Keryx," stated Michael S. Weiss, Chairman and CEO of the Company, who continued, "We recognize and are grateful for the dedication, diligence and compliance exhibited by the Collaborative Study Group and the more than 1,000 patients who participated in what is considered to be the largest ever randomized study for type 2 diabetic patients with persistent microalbuminuria."

Commenting on the news, Edmund J. Lewis, MD, co-Principal Investigator of the Phase 3 Study remarked, "We would like to commend both our Investigators and their patients for their level of commitment towards the completion of this pivotal 8-month study, marking the culmination of critical research in a disease area for which there has not been a novel treatment option in almost 15 years. We look forward to assembling and analyzing the data from this study."

A
'/>"/>

SOURCE Keryx Biopharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
4. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
5. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
6. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
9. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... LifeScienceIndustryResearch.com announces having a ... Global and China Lysine Industry to its research ... the deep research report in this field. For ... including definition, classification specifications, application, industry chain structure, ... Europe , Japan , ...
(Date:4/17/2015)... -- CVS Health Corporation (NYSE: CVS ) will ... 2015, at 8:30 a.m. (EDT) with analysts and investors ... An audio webcast of the conference call will be ... CVS Health website for all interested parties. To access ... be archived and available on the web site for ...
(Date:4/17/2015)... 2015  Trovagene, Inc., (NASDAQ:  TROV) a developer ... data presented at the 2015 European Lung Cancer ... Monitoring ℠ (PCM) platform outperformed tissue biopsy ... T790M mutations in metastatic lung cancer patients. ... Mutation in Urinary Circulating Tumor DNA from Metastatic ...
Breaking Medicine Technology:Lysine Market International (US, Europe, Japan) Research Analysis 2Lysine Market International (US, Europe, Japan) Research Analysis 3Lysine Market International (US, Europe, Japan) Research Analysis 4Lysine Market International (US, Europe, Japan) Research Analysis 5Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4
... MYL ) today announced that its subsidiary Mylan ... and Drug Administration (FDA) for its Abbreviated New Drug Application ... The company was the first to have filed a substantially ... for Clopidogrel Tablets, 300 mg, and was awarded 180 days ...
... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... the development, assembly, marketing and sale of medical devices ... will present at the CFA 2012 Cross-Continental Summit on ... Hotel in Shanghai on May 18, 2012. ...
Cached Medicine Technology:Mylan Launches Generic Version of Plavix® Tablets 2Dehaier Medical to Present at the CFA 2012 Cross-Continental Summit on Investment in Shanghai 2
(Date:4/17/2015)... April 17, 2015 Baptist Health and ... signed a partnership agreement designed to transform oncology care ... institutions have agreed to create a joint cancer program ... and translational research. Baptist MD Anderson Cancer Center is ... a single destination for highly coordinated, multidisciplinary cancer care ...
(Date:4/17/2015)... 2015 Scientists from the Icahn ... of U.S. and Venezuelan researchers, have discovered the ... among an isolated tribe of Yanomami Amerindians in ... in the Yanomami, previously unexposed to antibiotics or ... that of people living in industrialized countries, and ...
(Date:4/17/2015)... TX (PRWEB) April 17, 2015 Connie ... specialist and functional medicine advocate with 30 years of ... will be adding another level of service for her ... her website of 10 recommended wellness books with a ... When asked to explain her interest in providing this ...
(Date:4/17/2015)... Compare-autoinsurance.org has released a new blog ... auto insurance quotes . , The online environment ... their cars. Drivers should always compare multiple car insurance ... market is a competitive one, which means that customers ... , It is now possible to compare online car ...
(Date:4/17/2015)... April 17, 2015 Oxytocin ... posterior pituitary and thought to help mothers bond to ... To further substantiate this, new studies performed, at NYU ... Nature, and reported by Medical News Today on April ... influence over maternal social behavior. The study reveals that, ...
Breaking Medicine News(10 mins):Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3Health News:Connie Casad, M.D. Provides Patients Recommended List of Wellness Books on Website 2Health News:The Best Auto Insurance Quotes Are Available Online! 2Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 2Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 3
... Team of researchers at the University of NSW in Sydney have ... ,This is a 3D motion cue which is dynamic //half-occlusion. ... motion. ,It appears as a free access ... ,Building on principles of binocular geometry established by Leonardo ...
... study initiated by U.S. researchers on the medical histories ... were either blind or suffered weak eyesight, revealed that ... caused Vitamin A deficiency, leading to poor eyesight or ... issue of the British Journal of Ophthalmology. ...
... study has brought out the immense health benefits of ... behavioral attributes, even before //they arrive into the world. ... significantly lowered with consumption of fish oil by the ... double, because it directly impacts the unborn baby as ...
... depression, anxiety, suicidal thoughts and other mental health problems ... image than others - a study of adolescents in ... Dyl of Brown Medical School in Providence, Rhode Island ... body shape and weight are likely to be suffer ...
... cancer can talk to doctor through their beloved ones, especially ... ,The head of the Prostate Cancer Foundation, Leslie ... are daughters, wives and partners whom can realize their role ... prostrate cancer. ,More than 27,000 men were ...
... on the rise have brought the world to stand and ... future generations //. The American College of Cardiology (ACC) and ... pays attention to valvular heart disease. ,Valve ... flow between the left atrium and the left ventricle, or ...
Cached Medicine News:
Knowles Pins are available in 9" (228mm) overall length with 9/64" (3.5mm) shaft diameter and 1/4" (6.4mm) square bead....
... is the anterior alternative to the Ray TFC ... the same 70% fenestrations as Ray TFC. The ... in the formation of new bone. As with ... load sharing between the device and the spine.* ...
... Ray Threaded Fusion Cage is a proven interbody* ... IDE). This device is a hollow threaded cylinder ... this contact the device promotes spinal fusion by ... Ray TFC is indicated for use with autogenous ...
... Donor Screening: The Procleix System ... safety to the nation's blood supply. It ... target capture, and a unique nucleic acid ... HIV-1/HCV Assay can simultaneously detect the presence ...
Medicine Products: